GSK (LON:GSK) Earns "Buy" Rating from Shore Capital

Key Points

• Shore Capital reissued a buy rating for GSK, setting a target price of GBX 2,100, indicating a potential upside of 41.89% from its last closing price.
• GSK has an average rating of Hold from analysts, with various price targets ranging from GBX 1,400 to GBX 1,600.
• Insider Jonathan Symonds purchased 1,350 shares of GSK stock recently, signaling confidence in the company's future prospects.

GSK (LON:GSK - Get Free Report)'s stock had its "buy" rating reiterated by investment analysts at Shore Capital in a note issued to investors on Wednesday, Marketbeat reports. They presently have a GBX 2,100 target price on the stock. Shore Capital's price target would indicate a potential upside of 45.08% from the company's previous close.

Other equities research analysts have also issued reports about the company. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and set a GBX 1,450 target price on shares of GSK in a research report on Thursday, July 31st. Berenberg Bank reissued a "hold" rating and set a GBX 1,600 price target on shares of GSK in a research report on Friday, July 18th. Finally, JPMorgan Chase & Co. dropped their price target on GSK from GBX 1,460 to GBX 1,400 and set an "underweight" rating on the stock in a research report on Monday, August 4th. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold" and an average target price of GBX 1,637.50.

GSK Stock Performance

GSK stock traded down GBX 5 during mid-day trading on Wednesday, hitting GBX 1,447.50. 2,787,750 shares of the company's stock traded hands, compared to its average volume of 12,666,304. GSK has a one year low of GBX 1,242.50 and a one year high of GBX 1,678.68. The company has a quick ratio of 0.73, a current ratio of 0.81 and a debt-to-equity ratio of 114.64. The firm has a 50 day moving average price of GBX 1,414.75 and a 200 day moving average price of GBX 1,430.47. The company has a market cap of £58.41 billion, a PE ratio of 1,750.30, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31.

GSK (LON:GSK - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The company reported GBX 75.30 EPS for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. On average, equities analysts forecast that GSK will post 175.980975 EPS for the current year.

Insider Transactions at GSK

In other news, insider Jonathan Symonds bought 1,350 shares of the stock in a transaction on Friday, June 20th. The shares were purchased at an average price of GBX 1,435 per share, for a total transaction of £19,372.50. Also, insider Wendy Becker purchased 545 shares of the firm's stock in a transaction dated Friday, June 20th. The shares were bought at an average price of GBX 1,435 per share, with a total value of £7,820.75. Insiders acquired 1,913 shares of company stock worth $2,744,669 in the last 90 days. Corporate insiders own 0.20% of the company's stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.